Eivind Berge

Eivind Berge

Auto-generated profile, based on publicly available information

Eivind Berge

Department of Cardiology, Oslo University Hospital Ullevaal, Norway

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2018 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MMMaria H Mehlum
Maria H Mehlum
KLKnut Liestøl
Knut Liestøl
SKSverre E Kjeldsen
Sverre E Kjeldsen
SJStevo Julius
Stevo Julius
THTsushung A Hua
Tsushung A Hua
EBEivind Berge
Eivind Berge
Blood pressure variability is associated with increased risk of cardiovascular events, particularly in high-risk patients. We assessed if variability was associated with increased risk of cardiovascular events and death in hypertensive patients at different risk levels. The Valsartan Antihypertensive Long-term Use Evaluation trial was a randomized controlled trial of valsartan vs. amlodipine in patients with hypertension and different risks of cardiovascular events, followed for a mean of 4.2 years. We calculated standard deviation (SD) of mean systolic blood pressure from visits from 6 months onward in patients with ≥3 visits and no events during the first 6 months. We compared the risk of cardiovascular events in the highest and lowest quintile of visit-to-visit blood pressure variability, using Cox regression. For analysis of death, variability was analysed as a continuous variable. Of 13 803 patients included, 1557 (11.3%) had a cardiovascular event and 1089 (7.9%) died. Patients in the highest quintile of SD had an increased risk of cardiovascular events [hazard ratio (HR) 2.1, 95% confidence interval (95% CI) 1.7–2.4; P < 0.0001], and a 5 mmHg increase in SD of systolic blood pressure was associated with a 10% increase in the risk of death (HR 1.10, 95% CI 1.04–1.17; P = 0.002). Associations were stronger among younger patients and patients with lower systolic blood pressure, and similar between patients with different baseline risks, except for higher risk of death among patients with established cardiovascular disease. Higher visit-to-visit systolic blood pressure variability is associated with increased risk of cardiovascular events in patients with hypertension, irrespective of baseline risk of cardiovascular events. Associations were stronger in younger patients and in those with lower mean systolic blood pressure.

8 July 2013 in Trials
Verified
Journal Article
Open access
PDF file
EHErik Jrj van der Hoeven
Erik Jrj van der Hoeven
WSWouter J Schonewille
Wouter J Schonewille
JVJan Albert Vos
Jan Albert Vos
AAAle Algra
Ale Algra
HAHeinrich J Audebert
Heinrich J Audebert
JKJaap L Kappelle
Jaap L Kappelle
Background: Despite recent advances in acute stroke treatment, basilar artery occlusion (BAO) is associated with a death or disability rate of close to 70%. Randomised trials have shown the safety and efficacy of intravenous thrombolysis (IVT) given within 4.5 h and have shown promising results of intra-arterial thrombolysis given within 6 h of symptom onset of acute ischaemic stroke, but these results do not directly apply to patients with an acute BAO because only few, if any, of these patients were included in randomised acute stroke trials. Recently the results of the Basilar Artery International Cooperation Study (BASICS), a prospective registry of patients with acute symptomatic BAO challenged the often-held assumption that intra-arterial treatment (IAT) is superior to IVT. Our observations in the BASICS registry underscore that we continue to lack a proven treatment modality for patients with an acute BAO and that current clinical practice varies widely. Design: BASICS is a randomised controlled, multicentre, open label, phase III intervention trial with blinded outcome assessment, investigating the efficacy and safety of additional IAT after IVT in patients with BAO. The trial targets to include 750 patients, aged 18 to 85 years, with CT angiography or MR angiography confirmed BAO treated with IVT. Patients will be randomised between additional IAT followed by optimal medical care versus optimal medical care alone. IVT has to be initiated within 4.5 h from estimated time of BAO and IAT within 6 h. The primary outcome parameter will be favourable outcome at day 90 defined as a modified Rankin Scale score of 0–3. Discussion: The BASICS registry was observational and has all the limitations of a non-randomised study. As the IAT approach becomes increasingly available and frequently utilised an adequately powered randomised controlled phase III trial investigating the added value of this therapy in patients with an acute symptomatic BAO is needed (clinicaltrials.gov: NCT01717755).

17 June 2008 in Trials
Verified
Journal Article
Open access
PDF file
PSPeter Sandercock
Peter Sandercock
RLRichard Lindley
Richard Lindley
JWJoanna M Wardlaw
Joanna M Wardlaw
MDMartin Dennis
Martin Dennis
SLSteff Lewis
Steff Lewis
PLPhillippe Lyrer
Phillippe Lyrer
Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24–48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0–2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). ISRCTN25765518

1 December 2015 in Stroke
Verified
Journal Article
Closed access
EBEivind Berge
Eivind Berge
GCGeoffrey Cohen
Geoffrey Cohen
RLRichard I. Lindley
Richard I. Lindley
PSPeter Sandercock
Peter Sandercock
JWJoanna M Wardlaw
Joanna M Wardlaw
WWWilliam Whiteley
William Whiteley
Background and Purpose—: In patients with acute ischemic stroke, a high blood pressure or a highly variable blood pressure is a common reason for withholding thrombolytic treatment, but guidelines recommend a conservative approach to active blood pressure lowering in this setting. We have performed exploratory analyses to study the clinical effects of blood pressure and early blood pressure–lowering treatment in patients included in a randomized-controlled trial of thrombolytic treatment for acute ischemic stroke. Methods—: The Third International Stroke Trial (IST-3) randomized 3035 patients with ischemic stroke to recombinant tissue-type plasminogen activator 0.9 mg/kg or open control within 6 hours of symptom onset. Blood pressure was measured at randomization, at start of treatment, and at 30 minutes and 1 and 24 hours after start of treatment, and the use of blood pressure–lowering treatment during the first 24 hours was recorded. We have characterized blood pressure by mean systolic blood pressure at baseline, by variability of systolic blood pressure (expressed by the standard deviation and the range between the lowest and the highest pressure), and by the change in systolic blood pressure from baseline to 24 hours. We used logistic regression analysis to explore the associations of blood pressure characteristics or blood pressure–lowering treatment with early adverse events, early death, and functional outcome at 6 months, after adjustment for key prognostic variables. Results—: High baseline blood pressure and high blood pressure variability during the first 24 hours were associated with higher numbers of early adverse events and early deaths, and for several analyses, the differences were statistically significant. A larger decline in blood pressure and the use of blood pressure–lowering treatment during the first 24 hours were associated with a reduced risk of poor outcome at 6 months (odds ratio, 0.93; 95% confidence interval, 0.89–0.97; P =0.001 and odds ratio, 0.78; 95% confidence interval, 0.65–0.93; P =0.007, respectively), irrespective of whether the patient was given recombinant tissue-type plasminogen activator ( P values for interaction >0.05). Conclusions—: Among patients with ischemic stroke who are candidates for thrombolytic treatment, high baseline blood pressure and a large pressure variability during the first 24 hours may be associated with a poor prognosis, whereas a large reduction in blood pressure and the use of blood pressure–lowering treatment during the first 24 hours may be associated with a favorable prognosis. These data support the rationale for further trials of agents that lower blood pressure or reduce blood pressure variability in the acute phase of ischemic stroke. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00120003.

1 September 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
EBEivind Berge
Eivind Berge
GCGeoffrey Cohen
Geoffrey Cohen
MRMelinda B Roaldsen
Melinda B Roaldsen
ELErik Lundström
Erik Lundström
EIEva Isaksson
Eva Isaksson
WWWilliam N Whiteley
William N Whiteley

21 October 2002 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
EBEivind Berge
Eivind Berge
PSPeter Ag Sandercock
Peter Ag Sandercock